)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
SAB Biotherapeutics (SABS) investor relations material
SAB Biotherapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary7 Aug, 2025
Executive summary
Lead candidate SAB-142 advanced after positive Phase 1 data, with FDA alignment on pivotal Phase 2b SAFEGUARD study; study initiation planned for Q3 2025.
$175 million raised in July 2025 through an oversubscribed private placement, including strategic investor Sanofi, to fund clinical trials and extend operational runway to mid-2028.
No revenue recognized in Q2 2025 due to prior government grant terminations; focus remains on clinical development for type 1 diabetes and other autoimmune indications.
Completed full randomization of Phase 1 study for SAB-142; final data expected Q4 2025.
Financial highlights
Net loss of $10.1 million for Q2 2025, compared to $7.3 million in Q2 2024; net loss of $15.3 million for the six months ended June 30, 2025, versus $12.4 million year-over-year.
Cash and cash equivalents were $3.7 million as of June 30, 2025, down from $17.2 million at June 30, 2024; another source reports $5.7 million as of June 30, 2025.
R&D expenses were $7.0 million for Q2 2025, slightly up from $6.8 million in Q2 2024; general and administrative expenses fell to $2.7 million from $3.6 million.
No revenue in Q2 2025; revenue was $0.3 million in Q2 2024 and $1.2 million for the six months ended June 30, 2024.
Other income (loss) was $(0.4) million in Q2 2025, down from $2.9 million in Q2 2024, mainly due to changes in warrant liabilities and lower net interest income.
Outlook and guidance
Proceeds from the private placement are expected to fully fund the pivotal Phase 2b SAFEGUARD study and extend cash runway into mid-2028.
Existing resources expected to cover operating cash needs for at least twelve months post-report.
Anticipates continued net losses as clinical development progresses; expects R&D expenses to increase with advancement of SAB-142 into Phase 2b and other pipeline activities.
Final Phase 1 data for SAB-142 anticipated in Q4 2025; pivotal Phase 2b study to begin in Q3 2025.
Exploring additional funding options and potential partnerships for pipeline development.
Explain the rationale for Sanofi's investment.
Detail the planned use of private placement proceeds.
Elaborate on the warrant exercise milestone conditions.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next SAB Biotherapeutics earnings date
Q3 20255 Nov, 2025
Next SAB Biotherapeutics earnings date
Q3 20255 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
SAB Biotherapeutics Inc. is a biotechnology company focused on developing immunotherapies using its proprietary DiversitAb platform. The company specializes in producing targeted, fully human polyclonal antibodies for infectious diseases, autoimmune disorders, and other conditions. SAB Biotherapeutics leverages genetically engineered cattle to generate scalable and high-potency antibody treatments. The company is headquartered in Sioux Falls, South Dakota, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage